Advertisement
The interview covers topics including Immunosyn's immediate focus, itsfuture development and its market potential, the shift in the pharmaceuticalindustry toward biologically-derived drugs, the science behind SF-1019, therole of Argyll Biotechnologies, LLC its strategic partner and largestshareholder, Immunosyn's financial picture, the US and European regulatoryapproval process as it pertains to SF-1019 trials and milestones for which thepublic and investors should watch.
Advertisement
"We are pleased to be included with CEOCFO's esteemed collection ofcompanies. This interview offers us the opportunity to present noteworthyannouncements to brokers, institutional managers and individual investors aspart of our strategic market communication plan," says Stephen D. Ferrone.
About CEOCFO Interviews & News http://ceocfointerviews.com:
CEOCFO Interviews & News is a bi-weekly print online publication,marketing engine featuring publicly traded & venture capital companies on theU.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets) and Canadian (TSX & TSX-V)stock exchanges, Investment & Money Management Ideas.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans tomarket and distribute life enhancing therapeutics. Currently, the company hasexclusive worldwide rights from its largest shareholder, ArgyllBiotechnologies, LLC, to market, sell and distribute SF-1019, a compound thatwas developed from extensive research into Biological Response Modifiers(BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatoryapproval of SF-1019 in several countries and preparations for clinical trialsare underway in both the US and Europe. Research suggests that SF-1019 hasthe potential to affect a number of clinical conditions includingcomplications from Diabetic Mellitus such as Diabetic Neuropathy (DN) anddiabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS)and neurological disorders such as Chronic Inflammatory DemyelinatingPolyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).
The above news release contains forward-looking statements. Thesestatements are based on assumptions that management believes are reasonablebased on currently available information, and include statements regarding theintent, belief or current expectations of the Company and its management.Prospective investors are cautioned that any such forward-looking statementsare not guarantees of future performance, and are subject to a wide range ofbusiness risks, external factors and uncertainties. Actual results may differmaterially from those indicated by such forward-looking statements. Foradditional information, please consult the Company's most recent publicfilings and Annual Report on Form 10-K for its most recent fiscal year. TheCompany assumes no obligation to update the information contained in thispress release, whether as a result of new information, future events orotherwise.
SOURCE Immunosyn Corporation
